Ocular Therapeutix, Inc. (OCUL)
6.96
-0.33
(-4.53%)
USD |
NASDAQ |
Oct 02, 16:00
6.98
+0.02
(+0.29%)
After-Hours: 20:00
Ocular Therapeutix Net Income (Quarterly) : -78.76M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -78.76M |
| March 31, 2026 | -88.61M |
| December 31, 2025 | -64.65M |
| September 30, 2025 | -69.42M |
| June 30, 2025 | -67.81M |
| March 31, 2025 | -64.05M |
| December 31, 2024 | -48.39M |
| September 30, 2024 | -36.49M |
| June 30, 2024 | -43.78M |
| March 31, 2024 | -64.85M |
| December 31, 2023 | -29.22M |
| September 30, 2023 | -0.516M |
| June 30, 2023 | -20.68M |
| March 31, 2023 | -30.32M |
| December 31, 2022 | -15.54M |
| September 30, 2022 | -24.19M |
| June 30, 2022 | -18.77M |
| March 31, 2022 | -12.54M |
| December 31, 2021 | -3.85M |
| September 30, 2021 | 2.657M |
| June 30, 2021 | -8.481M |
| March 31, 2021 | 3.121M |
| December 31, 2020 | -85.61M |
| September 30, 2020 | -11.94M |
| June 30, 2020 | -36.57M |
| Date | Value |
|---|---|
| March 31, 2020 | -21.51M |
| December 31, 2019 | -26.02M |
| September 30, 2019 | -18.78M |
| June 30, 2019 | -24.45M |
| March 31, 2019 | -17.12M |
| December 31, 2018 | -17.40M |
| September 30, 2018 | -15.01M |
| June 30, 2018 | -13.80M |
| March 31, 2018 | -13.76M |
| December 31, 2017 | -13.10M |
| September 30, 2017 | -15.57M |
| June 30, 2017 | -18.69M |
| March 31, 2017 | -16.02M |
| December 31, 2016 | -12.82M |
| September 30, 2016 | -9.596M |
| June 30, 2016 | -11.44M |
| March 31, 2016 | -10.84M |
| December 31, 2015 | -10.64M |
| September 30, 2015 | -11.52M |
| June 30, 2015 | -10.01M |
| March 31, 2015 | -7.578M |
| December 31, 2014 | -7.954M |
| September 30, 2014 | -7.294M |
| June 30, 2014 | -6.397M |
| March 31, 2014 | -7.014M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| EyePoint, Inc. | -94.47M |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Theravance Biopharma, Inc. | -5.898M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 13.48M |
| Total Expenses (Quarterly) | 92.24M |
| EPS Diluted (Quarterly) | -0.3501 |
| Enterprise Value | 1.009B |
| Gross Profit Margin (Quarterly) | 85.08% |
| Profit Margin (Quarterly) | -584.5% |
| Earnings Yield | -20.30% |
| Normalized Earnings Yield | -20.35 |